STOCK TITAN

Azitra Inc - $AZTR STOCK NEWS

Welcome to our dedicated page for Azitra news (Ticker: $AZTR), a resource for investors and traders seeking the latest updates and insights on Azitra stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Azitra's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Azitra's position in the market.

Rhea-AI Summary
Azitra, Inc. announces new preclinical data to be presented at the American Society of Gene and Cell Therapy Meeting, showcasing the potential of ATR-12 for Netherton syndrome treatment. The data highlights significant reductions in IL-36g and protease activity, as well as enhanced delivery of LEKTI compared to topical application alone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.77%
Tags
-
Rhea-AI Summary
Azitra, Inc. (NYSE American: AZTR) is set to present new preclinical data at three upcoming scientific conferences in May 2024 focusing on innovative therapies for precision dermatology. The presentations will cover promising treatments for serious skin diseases using engineered Staphylococcus epidermidis strains.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.74%
Tags
conferences
-
Rhea-AI Summary
Azitra, Inc. (NYSE American: AZTR) reported financial results for FY 2023, highlighting an IPO that raised $7.5 million and IND clearance for ATR-12. The company advanced multiple clinical trials, strengthened IP portfolio, and engaged in strategic partnerships.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.04%
Tags
Rhea-AI Summary
Azitra, Inc. (AZTR) completes a public offering of 16,667,000 shares of common stock at $0.30 per share, raising approximately $5 million. The Company plans to use the proceeds for clinical trials, product development, research, manufacturing, and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Azitra, Inc. (AZTR) announces the pricing of a public offering of 16,667,000 shares of common stock at $0.30 per share, generating approximately $5 million in gross proceeds. The Company plans to use the funds for clinical trials, product development, research, manufacturing, and general corporate purposes. The offering is expected to close on February 16, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-73.91%
Tags
-
Rhea-AI Summary
Azitra, Inc. (NYSE American: AZTR) has been granted a patent for a strain of Staphylococcus epidermidis to treat ichthyosis vulgaris, a chronic skin disease with no FDA-approved treatment option affecting 1.3 million people in the US. This reinforces Azitra's commitment to precision dermatology and expands its intellectual property portfolio. The company is developing live biotherapeutic product candidates for IV, addressing the disease pathophysiology by delivering filaggrin to the skin.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
32.5%
Tags
none
Rhea-AI Summary
Azitra, Inc. (NYSE American: AZTR) to Present at Dermatology Summit and Biotech Showcase 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.43%
Tags
conferences
-
Rhea-AI Summary
Azitra, Inc. (NYSE American: AZTR) reported Q3 financial results, highlighting key pipeline advancements for precision dermatology therapies. The company provided updates on ATR-12 for Netherton syndrome, ATR-04 for EGFRi-associated rash, and its Joint Development Agreement with Bayer. Financially, the company disclosed $4.4 million in cash and cash equivalents and reported service revenue of $310,700 for Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.7%
Tags
-
Rhea-AI Summary
Azitra, Inc. to present at ThinkEquity Conference in New York City
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.59%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.52%
Tags
Azitra Inc

NYSE:AZTR

AZTR Rankings

AZTR Stock Data

7.49M
17.06M
18.88%
26.14%
0.7%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
BRANFORD

About AZTR

azitra, inc. is a preclinical stage biotechnology company harnessing the power of the microbiome to treat skin disease. the company was founded in 2014 by scientists from yale university and works with world-leading scientists in dermatology, microbiology, and genetic engineering to advance its programs in atopic dermatitis and targeted orphan indications. for more information visit www.azitrainc.com.